Global X China Biotech Innovation ETF (CHB)
| Assets | $2.30M |
| Expense Ratio | 0.65% |
| PE Ratio | 16.34 |
| Shares Out | n/a |
| Dividend (ttm) | $0.04 |
| Dividend Yield | 0.46% |
| Ex-Dividend Date | Jun 29, 2023 |
| Payout Ratio | 7.60% |
| 1-Year Return | -14.86% |
| Volume | 145 |
| Open | 8.05 |
| Previous Close | 8.14 |
| Day's Range | 8.05 - 8.05 |
| 52-Week Low | 7.11 |
| 52-Week High | 11.08 |
| Beta | n/a |
| Holdings | 45 |
| Inception Date | Sep 22, 2020 |
About CHB
Fund Home PageThe Global X China Biotech Innovation ETF (CHB) is an exchange-traded fund that is based on the Solactive China Biotech Innovation index. The fund tracks a market-cap weighted index of Chinese companies that are involved in the biotechnology industry. CHB was launched on Sep 22, 2020 and is issued by Global X.
Top 10 Holdings
60.73% of assets| Name | Symbol | Weight |
|---|---|---|
| CSPC Pharmaceutical Group Ltd | 1093.HK | 8.44% |
| Chongqing Zhifei Biological Products Co Ltd Class A | 300122.SZ | 8.38% |
| Changchun High and New Technology Industry Group Inc Class A | 000661.SZ | 8.18% |
| WuXi Biologics (Cayman) Inc | 2269.HK | 6.73% |
| Walvax Biotechnology Co Ltd Class A | 300142.SZ | 6.24% |
| Shanghai RAAS Blood Products Co Ltd Class A | 002252.SZ | 5.02% |
| Beijing Tiantan Biological Products Corp Ltd Class A | 600161.SS | 4.84% |
| Sichuan Kelun Pharmaceutical Co Ltd Class A | 002422.SZ | 4.45% |
| Hualan Biological Engineering Inc Class A | 002007.SZ | 4.35% |
| Genscript Biotech Corp Class H | 1548.HK | 4.11% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 29, 2023 | $0.03703 | Jul 10, 2023 |
| Jun 29, 2022 | $0.01989 | Jul 8, 2022 |
News
Capture the Growth Potential in China's Biotech Sector With This ETF
With China's economy recovering from a real estate development crisis and rising COVID-19 cases in 2022, it only sets up growth potential for 2023. One area of interest that exchange-traded fund (ETF)...
Capitalize on Biotech Growth in China With This ETF
After a rough 2021 that featured the Evergrande Crisis and heavy regulatory measures on technology to keep monopolistic moves in check, investors are eyeing opportunities in China. One of the sectors ...
Innovation Should Help Fuel Growth in This China Biotech ETF
Growth opportunities are abounding in Chinese biotech. A confluence of regulatory reforms, industry talent, and the re-opening of the country's capital markets have helped propel China's biotech indus...
The CHB ETF: China's Burgeoning Biotech Sector
As China continues to lead the global recovery, one area to keep a close eye on is biotechnology and the Global X China Biotech Innovation ETF (CHB). CHB seeks to provide investment results that corre...
China's Quest for a Covid-19 Vaccine Could Help Boost This ETF
All around the world, economic superpowers are vying to be the first to develop a vaccine for Covid-19. China is an obvious contender given that the country was the epicenter of the virus and their su...